The cellular effects of RBN2397 in preclinical models of lung cancer were attributed to reversal of a PARP7-TBK1 inhibitory mechanism that restores IFN signaling dependent on IRF3 (12). The gene discussed is IFNA1; the disease is lung carcinoma.